JP2023533040A - Ｗｅｅ１阻害剤の塩及び形態 - Google Patents

Ｗｅｅ１阻害剤の塩及び形態 Download PDF

Info

Publication number
JP2023533040A
JP2023533040A JP2023501229A JP2023501229A JP2023533040A JP 2023533040 A JP2023533040 A JP 2023533040A JP 2023501229 A JP2023501229 A JP 2023501229A JP 2023501229 A JP2023501229 A JP 2023501229A JP 2023533040 A JP2023533040 A JP 2023533040A
Authority
JP
Japan
Prior art keywords
degrees
compound
cancer
free base
range
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023501229A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022011391A5 (https=
JP2023533040A5 (https=
Inventor
ダニエル ホプキンス，チャド
キンファ ファン，ピーター
デュアン バンカー，ケビン
Original Assignee
リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー filed Critical リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー
Publication of JP2023533040A publication Critical patent/JP2023533040A/ja
Publication of JPWO2022011391A5 publication Critical patent/JPWO2022011391A5/ja
Publication of JP2023533040A5 publication Critical patent/JP2023533040A5/ja
Priority to JP2025156853A priority Critical patent/JP2025181949A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023501229A 2020-07-09 2021-07-08 Ｗｅｅ１阻害剤の塩及び形態 Pending JP2023533040A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025156853A JP2025181949A (ja) 2020-07-09 2025-09-22 Ｗｅｅ１阻害剤の塩及び形態

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063049996P 2020-07-09 2020-07-09
US63/049,996 2020-07-09
PCT/US2021/070851 WO2022011391A1 (en) 2020-07-09 2021-07-08 Salts and forms of a wee1 inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025156853A Division JP2025181949A (ja) 2020-07-09 2025-09-22 Ｗｅｅ１阻害剤の塩及び形態

Publications (3)

Publication Number Publication Date
JP2023533040A true JP2023533040A (ja) 2023-08-01
JPWO2022011391A5 JPWO2022011391A5 (https=) 2024-07-17
JP2023533040A5 JP2023533040A5 (https=) 2024-07-17

Family

ID=79552745

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023501229A Pending JP2023533040A (ja) 2020-07-09 2021-07-08 Ｗｅｅ１阻害剤の塩及び形態
JP2025156853A Pending JP2025181949A (ja) 2020-07-09 2025-09-22 Ｗｅｅ１阻害剤の塩及び形態

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025156853A Pending JP2025181949A (ja) 2020-07-09 2025-09-22 Ｗｅｅ１阻害剤の塩及び形態

Country Status (11)

Country Link
US (1) US12606567B2 (https=)
EP (1) EP4178960A4 (https=)
JP (2) JP2023533040A (https=)
KR (1) KR20230038523A (https=)
CN (1) CN116323613A (https=)
AU (1) AU2021305347A1 (https=)
BR (1) BR112023000350A2 (https=)
CA (1) CA3188737A1 (https=)
MX (1) MX2023000333A (https=)
TW (1) TWI896701B (https=)
WO (1) WO2022011391A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020384291A1 (en) 2019-11-15 2022-05-26 Recurium Ip Holdings, Llc Chiral synthesis of a tertiary alcohol
CN116462687B (zh) * 2022-01-18 2025-01-07 江苏天士力帝益药业有限公司 Wee1抑制剂及其制备和用途
EP4469086A4 (en) * 2022-01-25 2026-01-21 Verastem Inc POLYTHERAPY FOR THE TREATMENT OF ABNORMAL CELL GROWTH
JP2025525935A (ja) * 2022-08-05 2025-08-07 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー 子宮漿液性がんを治療するためのｗｅｅ１化合物
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
IL326136A (en) 2023-08-07 2026-03-01 Revolution Medicines Inc RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
WO2025076311A1 (en) * 2023-10-06 2025-04-10 Zeno Management, Inc. Solid forms of a wee1 inhibitor
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2338876A1 (en) * 2009-12-22 2011-06-29 LEK Pharmaceuticals d.d. Tamsulosin adipate for pharmaceutical use
WO2019173082A1 (en) * 2018-03-09 2019-09-12 Zeno Royalties & Milestones, LLC Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3071405A1 (en) 2017-08-01 2019-02-07 Recurium Ip Holdings, Llc 1, 2 - dihydro- 3h- pyrazolo [3, 4 - d] pyrimidin -3 - one analogs
WO2020210320A1 (en) 2019-04-11 2020-10-15 Recurium Ip Holdings, Llc Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
AU2020384291A1 (en) 2019-11-15 2022-05-26 Recurium Ip Holdings, Llc Chiral synthesis of a tertiary alcohol
WO2021127039A1 (en) 2019-12-20 2021-06-24 Recurium Ip Holdings, Llc Combinations
AU2020407070A1 (en) 2019-12-20 2022-07-14 Recurium Ip Holdings, Llc Combinations
MX2022007623A (es) 2019-12-20 2022-09-23 Recurium Ip Holdings Llc Combinaciones.
BR112022012280A2 (pt) 2019-12-20 2022-08-30 Recurium Ip Holdings Llc Combinações
AU2021271844A1 (en) 2020-05-15 2022-12-08 Recurium Ip Holdings, Llc Mono- and combination therapies
WO2021242667A1 (en) 2020-05-28 2021-12-02 Arizona Board Of Regents On Behalf Of The University Of Arizona Optical see-through head-mounted lightfield displays based on substrate-guided combiners
EP4153591A4 (en) * 2020-06-11 2024-01-24 Recurium IP Holdings, LLC METHOD FOR PRODUCING WEE1 INHIBITOR COMPOUNDS
WO2022136916A1 (en) 2020-12-22 2022-06-30 Recurium Ip Holdings, Llc Wee1 inhibitors and methods for treating cancer
AU2022259496A1 (en) 2021-04-12 2023-10-12 Recurium Ip Holdings, Llc Wee1 compound for treating uterine serous carcinoma
WO2022251224A1 (en) 2021-05-28 2022-12-01 Recurium Ip Holdings, Llc Wee1 inhibitors and methods for treating cancer
WO2022271731A1 (en) 2021-06-23 2022-12-29 Recurium Ip Holdings, Llc Wee1 inhibitors and methods for treating cancer
WO2023064282A1 (en) 2021-10-13 2023-04-20 Recurium Ip Holdings, Llc Combinations of wee 1 inhibitors and anti-cd47 antibodies.
WO2023076485A1 (en) 2021-10-28 2023-05-04 Recurium Ip Holdings, Llc Combination therapies comprising wee1 inhibitors and dna damage response (ddr) inhibitors
EP4447965A4 (en) 2021-12-15 2025-12-03 Recurium Ip Holdings Llc COMBINATIONS FOR TRIPLE THERAPY OF BCL-2 INHIBITORS, WEE-1 INHIBITORS AND OTHER CHEMOTHERAPEUTIC AGENTS
JP2024546569A (ja) 2021-12-15 2024-12-26 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー がんに対するｗｅｅ１阻害剤
KR20240119096A (ko) 2021-12-15 2024-08-06 리커리엄 아이피 홀딩스, 엘엘씨 암 치료를 위한 병용 요법 사용
JP2025525935A (ja) 2022-08-05 2025-08-07 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー 子宮漿液性がんを治療するためのｗｅｅ１化合物
EP4587026A1 (en) 2022-09-15 2025-07-23 Recurium IP Holdings, LLC Combinations
TW202421151A (zh) 2022-09-16 2024-06-01 美商瑞卡瑞恩Ｉｐ控股有限責任公司 Ｗｅｅ１抑制劑及用於治療癌症之方法
EP4615459A4 (en) 2022-11-08 2026-04-29 Zeno Man Inc Intermittent dosing regimen for azenosertib in treating cancer
KR20250094718A (ko) 2022-11-08 2025-06-25 제노 매니지먼트, 인크. Wee1 억제제로 암을 치료하기 위한 예측 바이오마커로서 시클린 e1 상태의 용도
TW202502354A (zh) 2023-06-02 2025-01-16 美商薩諾管理公司 同源重組修復缺陷（ｈｒｄ）作為預測性生物標記以便使用ｗｅｅ１抑制劑治療癌症
WO2025076311A1 (en) 2023-10-06 2025-04-10 Zeno Management, Inc. Solid forms of a wee1 inhibitor
WO2025106635A1 (en) 2023-11-15 2025-05-22 Zeno Management, Inc. Alteration of f-box and wd repeat domain containing 7 (fbxw7) gene as a predictive biomarker for treating cancer with wee1 inhibitors
WO2025179038A1 (en) 2024-02-21 2025-08-28 Recurium Ip Holdings, Llc Wee1 inhibitors and methods for treating cancer
WO2025184572A1 (en) 2024-03-01 2025-09-04 Zeno Management, Inc. Wee1 inhibitor combination therapy
WO2025188946A1 (en) 2024-03-07 2025-09-12 Recurium Ip Holdings, Llc Wee1 inhibitors and methods for treating cancer
WO2025193930A1 (en) 2024-03-14 2025-09-18 Zeno Management, Inc. Wee1 inhibitor combination therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2338876A1 (en) * 2009-12-22 2011-06-29 LEK Pharmaceuticals d.d. Tamsulosin adipate for pharmaceutical use
WO2019173082A1 (en) * 2018-03-09 2019-09-12 Zeno Royalties & Milestones, LLC Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
芦澤一英, 医薬品の多形現象と晶析の化学, JPN6015027444, 2002, pages 273 - 278, ISSN: 0005804857 *

Also Published As

Publication number Publication date
US20230265097A1 (en) 2023-08-24
TWI896701B (zh) 2025-09-11
NZ796125A (en) 2025-10-31
MX2023000333A (es) 2023-03-08
US12606567B2 (en) 2026-04-21
JP2025181949A (ja) 2025-12-11
CA3188737A1 (en) 2022-01-13
CN116323613A (zh) 2023-06-23
BR112023000350A2 (pt) 2023-03-28
EP4178960A4 (en) 2024-07-17
WO2022011391A1 (en) 2022-01-13
AU2021305347A1 (en) 2023-02-16
TW202216716A (zh) 2022-05-01
EP4178960A1 (en) 2023-05-17
KR20230038523A (ko) 2023-03-20

Similar Documents

Publication Publication Date Title
JP2023533040A (ja) Ｗｅｅ１阻害剤の塩及び形態
JP7710223B2 (ja) 置換ピロロトリアジン系化合物およびその医薬組成物並びにそれらの使用
JP2022517396A (ja) Ｅｇｆｒ阻害剤の塩、結晶形及びその製造方法
CN102295635B (zh) 抗肿瘤药物四氢化萘酰胺类化合物及其药学上可接受的盐及制备方法和应用
JP7669063B2 (ja) Ｂｔｋ阻害剤としての架橋二環式化合物
WO2025076311A1 (en) Solid forms of a wee1 inhibitor
CN101671337A (zh) 枸橼酸爱地那非晶型a及其制备方法和用途
JP2022553833A (ja) エストロゲン受容体調節薬の塩及び形態
KR20200116132A (ko) Cdk4/6 키나아제 억제제를 타겟팅하는 결정형
RU2858658C2 (ru) Соли и формы ингибитора wee1
US11945814B2 (en) Salt form
JP2022540466A (ja) 非晶質ウムブラリシブモノトシレート
CN105732642B (zh) 一种cdk抑制剂和mek抑制剂的共晶及其制备方法
EP4631937A1 (en) Crystalline form or amorphous form of oxoisoindole-5-formamide compound or salt and solvate thereof
TW202328138A (zh) 稠合二環類衍生物的可藥用鹽、晶型及其製備方法
US20200039967A1 (en) Novel forms of afatinib dimaleate
CN117466898A (zh) 氨基吡唑并嘧啶化合物的晶体
CN115490640A (zh) 取代的苯并咪唑类化合物及包含该化合物的组合物及其用途
CN117751121A (zh) 氨基吡唑并嘧啶化合物的晶体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240708

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240708

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250425

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250520

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250922

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250922

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251105